Rekombinanter MS4A1 (Rituximab Biosimilar) Antikörper

Produktnummer ABIN7200660

Der Maus Monoklonal Anti-MS4A1 (Rituximab Biosimilar)-Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, MS4A1 (Rituximab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter MS4A1 (Rituximab Biosimilar) Antikörper (ABIN7200660)

Target: MS4A1 (Rituximab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser MS4A1 (Rituximab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Klon: 10F381

Produktdetails anti-MS4A1 (Rituximab Biosimilar) Antikörper

Verwendungszweck: Rituximab Biosimilar, CD20 Monoclonal Antibody

Spezifität: The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha.

Produktmerkmale: Recombinant Humanized IgG1 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by rituximab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu MS4A1 (Rituximab Biosimilar)

Target: MS4A1 (Rituximab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.

Rituximab, a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.